Abstract
In the present work we described improvements in the 1-7 antiparasitic Morita-Baylis-Hillman Adducts synthesis and their antimitotic activity on sea urchin embryonic cells. The 2-[Hydroxy(2-nitrophenyl)methyl]acrylonitrile (1) and 2-[Hydroxy(4-bromophenyl) methyl]acrylonitrile (4) were the most effective compounds to block the progression to embryonic morula stage (EC50 = 75.8 M and 72.6 M, respectively). Compounds 1 and 4 were also effective in blocking the first cell division but to a lesser extent. The 2-[Hydroxy(pyridin-4-yl)methyl]acrylonitrile (7) exhibited a strong inhibition of cell divisions and progression to the first cleavage and morula stage. Fluorescent dye extrusion assay suggests that these adducts are not ABC protein substrates, which confers an additional interest in these new class of potential anticancer drugs.
Keywords: Antimitotic activities, Sea-urchin embryonic cells, Morita-Baylis-Hillman adducts, Cancer
Medicinal Chemistry
Title:Antimitotic Activity on Sea Urchin Embryonic Cells of Seven Antiparasitic Morita-Baylis-Hillman Adducts: A Potential New Class of Anticancer Drugs
Volume: 8 Issue: 6
Author(s): Jocelmo C. A. Leite, Claudio G. L. Junior, Fabio P. L. Silva, Suervy C.O. Sousa, Mario L. A. A. Vasconcellos and Luis F. Marques-Santos
Affiliation:
Keywords: Antimitotic activities, Sea-urchin embryonic cells, Morita-Baylis-Hillman adducts, Cancer
Abstract: In the present work we described improvements in the 1-7 antiparasitic Morita-Baylis-Hillman Adducts synthesis and their antimitotic activity on sea urchin embryonic cells. The 2-[Hydroxy(2-nitrophenyl)methyl]acrylonitrile (1) and 2-[Hydroxy(4-bromophenyl) methyl]acrylonitrile (4) were the most effective compounds to block the progression to embryonic morula stage (EC50 = 75.8 M and 72.6 M, respectively). Compounds 1 and 4 were also effective in blocking the first cell division but to a lesser extent. The 2-[Hydroxy(pyridin-4-yl)methyl]acrylonitrile (7) exhibited a strong inhibition of cell divisions and progression to the first cleavage and morula stage. Fluorescent dye extrusion assay suggests that these adducts are not ABC protein substrates, which confers an additional interest in these new class of potential anticancer drugs.
Export Options
About this article
Cite this article as:
C. A. Leite Jocelmo, G. L. Junior Claudio, P. L. Silva Fabio, C.O. Sousa Suervy, L. A. A. Vasconcellos Mario and F. Marques-Santos Luis, Antimitotic Activity on Sea Urchin Embryonic Cells of Seven Antiparasitic Morita-Baylis-Hillman Adducts: A Potential New Class of Anticancer Drugs, Medicinal Chemistry 2012; 8 (6) . https://dx.doi.org/10.2174/1573406411208061003
DOI https://dx.doi.org/10.2174/1573406411208061003 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Executive Guest Editor
Current Cancer Drug Targets Advances of Phenoxazines: Synthesis, Reactivity and Their Medicinal Applications
Current Medicinal Chemistry The Potential Clinical Impact of Probiotic Treatment for the Prevention and/or Anti-Inflammatory Therapeutic Effect Against Radiation Induced Intestinal Mucositis. A Review
Recent Patents on Inflammation & Allergy Drug Discovery CYP3A4-mediated Pharmacokinetic Interactions in Cancer Therapy
Current Drug Metabolism Keeping A Breast of Recent Developments in Cancer Metabolism
Current Drug Targets Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis
Current Pharmaceutical Design New Developments and Prospective Applications for β (1,3) Glucans
Recent Patents on Biotechnology Topoisomerase 1B as a Target Against Leishmaniasis
Mini-Reviews in Medicinal Chemistry Meet Our Associate Editor
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Discovery of HIF-1α-p300/CBP Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Palladium-Catalyzed Oxyarylation, Azaarylation and α-Arylation Reactions in the Synthesis of Bioactive Isoflavonoid Analogues
Current Organic Synthesis Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Recent Patents on Biomarkers Tumor-Targeted Drug Delivery with Aptamers
Current Medicinal Chemistry Novel Nanotechnology Approaches for Targeted Cancer Therapy
Recent Patents on Nanomedicine MEK Inhibitors: A Therapeutic Approach to Targeting the Ras-MAP Kinase Pathway in Tumors
Current Pharmaceutical Design 3D QSAR Pharmacophore Modeling for c-Met Kinase Inhibitors
Medicinal Chemistry Synthesis and Bioevaluation of Shikonin Derivatives
Letters in Drug Design & Discovery Review of Postoperative and Elective Nodal Irradiation in Head and Neck Cancer
Current Cancer Therapy Reviews Clinical Pharmacokinetics of Irinotecan-Based Chemotherapy in Colorectal Cancer Patients
Current Clinical Pharmacology Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery